Product: ZDHHC2 Antibody
Catalog: DF4688
Description: Rabbit polyclonal antibody to ZDHHC2
Application: WB IF/ICC
Cited expt.: WB
Reactivity: Human, Mouse, Rat, Monkey
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 42 KD; 42kD(Calculated).
Uniprot: Q9UIJ5
RRID: AB_2837039

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:1000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat,Monkey
Prediction:
Pig(89%), Bovine(89%), Horse(89%), Sheep(89%), Rabbit(89%), Dog(89%)
Clonality:
Polyclonal
Specificity:
ZDHHC2 Antibody detects endogenous levels of total ZDHHC2.
RRID:
AB_2837039
Cite Format: Affinity Biosciences Cat# DF4688, RRID:AB_2837039.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

DHHC-2; Palmitoyltransferase ZDHHC2; Ream; Rec; Reduced expression associated with metastasis protein; Reduced expression in cancer protein; ZDHC2_HUMAN; Zdhhc2; Zinc finger DHHC domain-containing protein 2; Zinc finger protein 372; ZNF372;

Immunogens

Immunogen:

A synthesized peptide derived from human ZDHHC2, corresponding to a region within the internal amino acids.

Uniprot:
Gene(ID):
Expression:
Q9UIJ5 ZDHC2_HUMAN:

Ubiquitously expressed. Reduced expression in colorectal cancers with liver metastasis.

Sequence:
MAPSGPGSSARRRCRRVLYWIPVVFITLLLGWSYYAYAIQLCIVSMENTGEQVVCLMAYHLLFAMFVWSYWKTIFTLPMNPSKEFHLSYAEKDLLEREPRGEAHQEVLRRAAKDLPIYTRTMSGAIRYCDRCQLIKPDRCHHCSVCDKCILKMDHHCPWVNNCVGFSNYKFFLLFLAYSLLYCLFIAATDLQYFIKFWTNGLPDTQAKFHIMFLFFAAAMFSVSLSSLFGYHCWLVSKNKSTLEAFRSPVFRHGTDKNGFSLGFSKNMRQVFGDEKKYWLLPIFSSLGDGCSFPTCLVNQDPEQASTPAGLNSTAKNLENHQFPAKPLRESQSHLLTDSQSWTESSINPGKCKAGMSNPALTMENET

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
89
Horse
89
Bovine
89
Sheep
89
Dog
89
Rabbit
89
Xenopus
67
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Palmitoyltransferase specific for GAP43 and DLG4/PSD95.

(Microbial infection) Promotes Chikungunya virus (CHIKV) replication by mediating viral nsp1 palmitoylation.

Subcellular Location:

Membrane>Multi-pass membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Ubiquitously expressed. Reduced expression in colorectal cancers with liver metastasis.

Family&Domains:

The DHHC domain is required for palmitoyltransferase activity.

Belongs to the DHHC palmitoyltransferase family.

References

1). ZDHHC2-Mediated AGK Palmitoylation Activates AKT-mTOR Signaling to Reduce Sunitinib Sensitivity in Renal Cell Carcinoma. Cancer research, 2023 (PubMed: 37078777) [IF=12.5]

Application: WB    Species: human    Sample: 786-O cells

Figure 1. ZDHHC2-mediated S-palmitoylation plays a key role in modulating the sensitivity of ccRCC to sunitinib. A, 786-O cells were transfected with indicated constructs for 72 hours. These cells were harvested and treated with a serial dose of sunitinib for 24 hours. The CCK-8 assay was applied to measure the IC50 values of sunitinib in each group. Data presents as mean ± SEM with three replicates. B, Expression levels of ZDHHCs during sunitinib pretreatment (n = 4), response (n = 4), and resistance (escape; n = 4) phases. The heatmap shows the log-fold change (LogFC) of escape versus pretreatment and log-fold change of escape versus response. C, The protein level of ZDHHC2 from patients with RCC with (n = 6) or without (n = 6) sunitinib resistance was examined by Western blotting analysis, and the protein level of ZDHHC2 was quantified by ImageJ software. P values as indicated. D, The protein level of ZDHHC2 from 786-O cells with or without sunitinib resistance (786-O R) was examined by Western blotting analysis. Three replicates were performed. E–G, 786-O cells were transfected with indicated constructs for 48 hours. After 24-hour puromycin selection, cells were treated with or without sunitinib (2 μmol/L) for another 24 hours. Cells were collected for Western blot analysis (E), caspase-3 activity assay (F), and Annexin V-FITC/7-AAD assay (G). Data presented as mean ± SEM with three replicates. H, 786-O, A498, and 786-O R cells were transfected with indicated constructs for 72 hours. After puromycin selection, these cells were treated with a serial dose of sunitinib for 24 hours and subjected to CCK-8 assay. The IC50 values of sunitinib in each group are indicated. I–K, 786-O cells were transfected with indicated constructs for 72 hours. After puromycin selection, these cells were subcutaneously injected into the nude mice. These mice were treated with or without sunitinib (oral administration, 25 mg/kg, once a day for 8 days). Tumor image (I); tumor mass (J); tumor growth curve (K). Data presented as mean ± SEM with five replicates. L and M, 786-O cells were transfected with indicated constructs for 24 hours. Cells were treated with or without sunitinib (2 μmol/L) for another 24 hours. Cells were collected for Western blot analysis (L) and caspase-3 activity assay (M). Data presented as mean ± SEM with three replicates. N, 786-O and A498 cells were transfected with indicated constructs for 24 hours. These cells were treated with a serial dose of sunitinib for 24 hours and subjected to CCK-8 assay. The IC50 values of sunitinib in each group are indicated. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001. EV, empty vector.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.